Although the Trump administration repeatedly promised to lower drug prices, the reality has been starkly different: prescription costs continue to climb, leaving Americans struggling while pharmaceutical companies thrive. Behind these soaring prices are CEOs inflating their paychecks, corporations shielded by government-funded research, and generous tax breaks that keep profits flowing.
The system is built to favor Big Pharma. Life-sustaining
drugs like insulin illustrate the problem most starkly: patients are forced
into impossible choices—buy medicine or pay rent. A deeper understanding of
this system is needed to uncover where all the money goes.
The path to affordable medicine requires meaningful
drug-pricing reform. Many of us have seen examples where people cannot afford
necessary medications. Below are the main drivers of high drug prices:
1. Drug makers’ profit motive
Pharmaceutical companies argue that drug development and
clinical trials are expensive and risky, with many failures along the way. Yet
a recent JAMA Network Open study found no connection between R&D
spending and drug prices. Even after accounting for R&D costs, most of the
top 30 pharmaceutical companies report billions in profit. In Europe, where
drug prices are negotiated, the same medicines often cost far less.
2. Pharmacy benefit managers (PBMs)
PBMs manage drug benefits for large employers, Medicare, and
insurers, deciding which drugs to cover and how much patients pay. Their
incentives—often tied to a percentage of overall spending—can encourage
approval of higher-priced drugs. State and federal lawmakers are increasingly
pushing for legislation to limit PBM influence and increase transparency.
3. Cost-sharing
Insurers have shifted more costs onto patients through
higher copays, deductibles, and premiums. While sometimes justified as a way to
discourage unnecessary care, this system often deters people from seeking
essential treatment.
4. Legal maneuvers
Drug makers extend monopolies by filing multiple patents,
suing potential competitors, or creating “me too” drugs with minor tweaks to
secure new protections. Others acquire patents for older drugs, then sharply
raise prices, or merge with rivals to suppress competition.
5. Direct-to-consumer advertising
Drug companies spend billions—nearly $8.1 billion in 2022—on advertising, which raises drug costs while fueling demand for newer, heavily marketed (and often more expensive) drugs. Most countries ban this practice; the U.S. remains a major exception.
What Might Slow Rising Drug Costs?
While prescription drug prices are unlikely to fall
dramatically anytime soon, several developments could help curb costs:
- The
Inflation Reduction Act of 2022. This law allows the U.S. government
to negotiate prices for certain Medicare drugs, beginning with 10
high-cost medications in 2026. More will follow annually, though the scope
remains limited given that over 20,000 drugs are on the market.
- Drug
importation and new legislation. The FDA recently approved Florida’s
plan to import drugs from Canada. Additional proposals at both state and
federal levels aim to expand access to lower-cost alternatives.
- Advocacy efforts. Organizations such as AARP, Consumers Union, and Patients for Affordable Drugs are amplifying public pressure on lawmakers, gaining more traction now than in the past.
Conclusion
According to Dr. Robert Shmerling, former clinical chief of
rheumatology at Beth Israel Deaconess Medical Center, the U.S. healthcare
system is structurally designed to reward high drug prices. While individuals
can take steps to reduce their out-of-pocket expenses, these efforts have
limits. Real progress requires systemic reform that removes middlemen and
eliminates incentives that inflate costs without adding value.
Until then, the most effective step individuals can take may
be preventive: staying as healthy as possible to reduce reliance on
prescription drugs. After all, the surest way to lower drug costs is not to
need them at all.
https://www.health.harvard.edu/blog/why-do-your-prescription-drugs-cost-so-much-202401183007